Skip to search formSkip to main contentSkip to account menu

Carbidopa / Levodopa

Known as: Carbidopa and Levodopa, co careldopa, carbidopa-levodopa 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
Background: Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated… 
Highly Cited
2004
Highly Cited
2004
BACKGROUND Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that… 
Highly Cited
2003
Highly Cited
2003
Objective: To characterize the relationships between symptoms of fatigue, physical activity, physical function, and functional… 
Review
2002
Review
2002
Drs. David S. Goldstein and Graeme Eisenhofer (Clinical Neurocardiology Section, National Institute of Neurological Disorders and… 
Highly Cited
1996
Highly Cited
1996
Carbidopa/levodopa has become accepted as a primary treatment for both the restless legs (RL) syndrome and periodic leg movements… 
Highly Cited
1993
Highly Cited
1993
We studied the relative benefits of carbidopa/levodopa (25/100 mg and 50/200 mg) and propoxyphene (100 mg and 200 mg) in six… 
Highly Cited
1985
Highly Cited
1985
Three cases of a syndrome resembling neuroleptic malignant syndrome are described in patients never exposed to neuroleptics. Each… 
Highly Cited
1974
Highly Cited
1974
  • S. Fahn
  • Neurology
  • 1974
  • Corpus ID: 29118595
Five parkinsonian patients with severe “on-off” effects from levodopa therapy also were given combination carbidopa/levodopa…